“…In addition, the response of the aPTT to UFH varies markedly with the kind of equipment, thromboplastic reagents, and timing that a laboratory uses, making interlaboratory variation important. 20,[23][24][25][26][27][28][29][30][31] Heparin activity, measured as either antifactor IIa 32,33 or antifactor Xa34 activity, has been considered too expensive and cumbersome to be used for routine monitoring [6][7][8] despite the fact that the assay is available in over 4000 laboratories in France alone. 8 Technologic improvements have made the assays much easier to perform, and it might be a more accurate way to monitor therapy in at least some subgroups of patients.…”